Raras
Buscar doenças, sintomas, genes...
Leucoencefalopatia de Cree
ORPHA:99854CID-10 · E75.2CID-11 · 8A44.3OMIM 603896DOENÇA RARA

Qualquer tipo de leucoencefalopatia (uma doença cerebral que afeta a substância branca) em que essa substância branca vai desaparecendo, e cuja causa é uma alteração genética no gene EIF2B1.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Qualquer tipo de leucoencefalopatia (uma doença cerebral que afeta a substância branca) em que essa substância branca vai desaparecendo, e cuja causa é uma alteração genética no gene EIF2B1.

Pesquisas ativas
2 ensaios
7 total registrados no ClinicalTrials.gov
Publicações científicas
10 artigos
Último publicado: 2026 Feb
🏥
SUS: Cobertura mínimaScore: 20%
CID-10: E75.2
🇧🇷Dados SUS / DATASUS2024
890
internações/ano
R$ 45.670
custo médio/internação
ESTADOS COM MAIS INTERNAÇÕES
SPRJMGRSPR
PROCEDIMENTOS SIGTAP (8)
0202010279
Dosagem de aminoácidos (erros inatos)metabolic_test
0202010295
Dosagem de ácidos orgânicos na urinagenetic_test
0202010490
Teste de triagem para erros inatos do metabolismonewborn_screening
0202010694
Sequenciamento completo do exoma (WES)enzyme_replacement
0202080013
Teste do pezinho (triagem neonatal)rehabilitation
0303050101
Infusão de imiglucerase (Gaucher)
+2 outros procedimentos
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
9 sintomas
📏
Crescimento
2 sintomas
👁️
Olhos
2 sintomas
🫘
Rins
2 sintomas

+ 14 sintomas em outras categorias

Características mais comuns

55%prev.
Macrocefalia
Frequente (79-30%)
55%prev.
Início juvenil
17%prev.
Cegueira
Ocasional (29-5%)
Letargia
Convulsão
Cessação do crescimento da cabeça
29sintomas
Frequente (2)
Ocasional (1)
Sem dados (26)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 29 características clínicas mais associadas, ordenadas por frequência.

MacrocefaliaMacrocephaly
Frequente (79-30%)55%
Início juvenilJuvenile onset
Frequente55%
CegueiraBlindness
Ocasional (29-5%)17%
LetargiaLethargy
ConvulsãoSeizure

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico10PubMed
Últimos 10 anos2publicações
Pico20251 papers
Linha do tempo
2026Hoje · 2026🧪 2012Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

5 genes identificados com associação a esta condição.

Autosomal recessive
EIF2B5Translation initiation factor eIF2B subunit epsilonDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Acts as a component of the translation initiation factor 2B (eIF2B) complex, which catalyzes the exchange of GDP for GTP on eukaryotic initiation factor 2 (eIF2) gamma subunit (PubMed:25858979, PubMed:27023709, PubMed:31048492). Its guanine nucleotide exchange factor activity is repressed when bound to eIF2 complex phosphorylated on the alpha subunit, thereby limiting the amount of methionyl-initiator methionine tRNA available to the ribosome and consequently global translation is repressed (Pub

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Recycling of eIF2:GDP
MECANISMO DE DOENÇA

Leukoencephalopathy with vanishing white matter 5

An autosomal recessive brain disease characterized by neurological features including progressive cerebellar ataxia, spasticity, and cognitive deficits. Brain imaging shows abnormal white matter that vanishes over time and is replaced by cerebrospinal fluid. Disease severity ranges from fatal infantile forms to adult forms without neurological deterioration. The disease is progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. Death may occurs after a variable period after disease onset, usually following an episode of fever and coma. A subset of affected females with milder forms of the disease who survive to adolescence exhibit ovarian dysfunction. This variant of the disorder is called ovarioleukodystrophy.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
71.5 TPM
Cerebelo
70.8 TPM
Cervix Endocervix
59.6 TPM
Pituitária
59.6 TPM
Próstata
59.6 TPM
OUTRAS DOENÇAS (6)
leukoencephalopathy with vanishing white matter 5juvenile or adult CACH syndromecongenital or early infantile CACH syndromelate infantile CACH syndrome
HGNC:3261UniProt:Q13144
EIF2B2Translation initiation factor eIF2B subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a component of the translation initiation factor 2B (eIF2B) complex, which catalyzes the exchange of GDP for GTP on eukaryotic initiation factor 2 (eIF2) gamma subunit (PubMed:25858979, PubMed:27023709, PubMed:31048492). Its guanine nucleotide exchange factor activity is repressed when bound to eIF2 complex phosphorylated on the alpha subunit, thereby limiting the amount of methionyl-initiator methionine tRNA available to the ribosome and consequently global translation is repressed (Pub

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Recycling of eIF2:GDP
MECANISMO DE DOENÇA

Leukoencephalopathy with vanishing white matter 2

An autosomal recessive brain disease characterized by neurological features including progressive cerebellar ataxia, spasticity, and cognitive deficits. Brain imaging shows abnormal white matter that vanishes over time and is replaced by cerebrospinal fluid. Disease severity ranges from fatal infantile forms to adult forms without neurological deterioration. The disease is progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. Death may occurs after a variable period after disease onset, usually following an episode of fever and coma. A subset of affected females with milder forms of the disease who survive to adolescence exhibit ovarian dysfunction. This variant of the disorder is called ovarioleukodystrophy.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
37.5 TPM
Artéria tibial
26.8 TPM
Testículo
25.3 TPM
Fibroblastos
25.2 TPM
Glândula adrenal
22.0 TPM
OUTRAS DOENÇAS (6)
leukoencephalopathy with vanishing white matter 2juvenile or adult CACH syndromelate infantile CACH syndromecongenital or early infantile CACH syndrome
HGNC:3258UniProt:P49770
EIF2B4Translation initiation factor eIF2B subunit deltaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a component of the translation initiation factor 2B (eIF2B) complex, which catalyzes the exchange of GDP for GTP on eukaryotic initiation factor 2 (eIF2) gamma subunit (PubMed:25858979, PubMed:27023709, PubMed:31048492). Its guanine nucleotide exchange factor activity is repressed when bound to eIF2 complex phosphorylated on the alpha subunit, thereby limiting the amount of methionyl-initiator methionine tRNA available to the ribosome and consequently global translation is repressed (Pub

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Recycling of eIF2:GDP
MECANISMO DE DOENÇA

Leukoencephalopathy with vanishing white matter 4

An autosomal recessive brain disease characterized by neurological features including progressive cerebellar ataxia, spasticity, and cognitive deficits. Brain imaging shows abnormal white matter that vanishes over time and is replaced by cerebrospinal fluid. Disease severity ranges from fatal infantile forms to adult forms without neurological deterioration. The disease is progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. Death may occurs after a variable period after disease onset, usually following an episode of fever and coma. A subset of affected females with milder forms of the disease who survive to adolescence exhibit ovarian dysfunction. This variant of the disorder is called ovarioleukodystrophy.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
93.0 TPM
Cervix Endocervix
68.4 TPM
Próstata
65.7 TPM
Nervo tibial
65.3 TPM
Cólon sigmoide
60.3 TPM
OUTRAS DOENÇAS (6)
leukoencephalopathy with vanishing white matter 4late infantile CACH syndromejuvenile or adult CACH syndromecongenital or early infantile CACH syndrome
HGNC:3260UniProt:Q9UI10
EIF2B3Translation initiation factor eIF2B subunit gammaDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Acts as a component of the translation initiation factor 2B (eIF2B) complex, which catalyzes the exchange of GDP for GTP on the eukaryotic initiation factor 2 (eIF2) complex gamma subunit (PubMed:25858979, PubMed:27023709, PubMed:31048492). Its guanine nucleotide exchange factor activity is repressed when bound to eIF2 complex phosphorylated on the alpha subunit, thereby limiting the amount of methionyl-initiator methionine tRNA available to the ribosome and consequently global translation is re

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Recycling of eIF2:GDP
MECANISMO DE DOENÇA

Leukoencephalopathy with vanishing white matter 3

An autosomal recessive brain disease characterized by neurological features including progressive cerebellar ataxia, spasticity, and cognitive deficits. Brain imaging shows abnormal white matter that vanishes over time and is replaced by cerebrospinal fluid. Disease severity ranges from fatal infantile forms to adult forms without neurological deterioration. The disease is progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. Death may occurs after a variable period after disease onset, usually following an episode of fever and coma. A subset of affected females with milder forms of the disease who survive to adolescence exhibit ovarian dysfunction. This variant of the disorder is called ovarioleukodystrophy.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
31.1 TPM
Nervo tibial
26.6 TPM
Fibroblastos
25.3 TPM
Testículo
24.9 TPM
Cervix Ectocervix
23.6 TPM
OUTRAS DOENÇAS (6)
leukoencephalopathy with vanishing white matter 3juvenile or adult CACH syndromeobsolete ovarioleukodystrophycongenital or early infantile CACH syndrome
HGNC:3259UniProt:Q9NR50
EIF2B1Translation initiation factor eIF2B subunit alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a component of the translation initiation factor 2B (eIF2B) complex, which catalyzes the exchange of GDP for GTP on eukaryotic initiation factor 2 (eIF2) gamma subunit (PubMed:25858979, PubMed:27023709, PubMed:31048492). Its guanine nucleotide exchange factor activity is repressed when bound to eIF2 complex phosphorylated on the alpha subunit, thereby limiting the amount of methionyl-initiator methionine tRNA available to the ribosome and consequently global translation is repressed (Pub

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Recycling of eIF2:GDP
MECANISMO DE DOENÇA

Leukoencephalopathy with vanishing white matter 1

An autosomal recessive brain disease characterized by neurological features including progressive cerebellar ataxia, spasticity, and cognitive deficits. Brain imaging shows abnormal white matter that vanishes over time and is replaced by cerebrospinal fluid. Disease severity ranges from fatal infantile forms to adult forms without neurological deterioration. The disease is progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. Death may occurs after a variable period after disease onset, usually following an episode of fever and coma. A subset of affected females with milder forms of the disease who survive to adolescence exhibit ovarian dysfunction. This variant of the disorder is called ovarioleukodystrophy.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Útero
67.5 TPM
Cervix Endocervix
63.4 TPM
Linfócitos
62.4 TPM
Cervix Ectocervix
61.6 TPM
Ovário
59.6 TPM
OUTRAS DOENÇAS (5)
leukoencephalopathy with vanishing white matter 1juvenile or adult CACH syndromecongenital or early infantile CACH syndromelate infantile CACH syndrome
HGNC:3257UniProt:Q14232

Variantes genéticas (ClinVar)

186 variantes patogênicas registradas no ClinVar.

🧬 EIF2B1: NM_001414.4(EIF2B1):c.824A>T (p.Tyr275Phe) ()
🧬 EIF2B1: NM_001414.4(EIF2B1):c.816G>A (p.Trp272Ter) ()
🧬 EIF2B1: GRCh37/hg19 12q23.1-24.33(chr12:99532287-133777902)x3 ()
🧬 EIF2B1: GRCh37/hg19 12q24.21-24.33(chr12:116422123-133777902)x3 ()
🧬 EIF2B1: GRCh37/hg19 12q24.22-24.33(chr12:117533207-133777902)x3 ()
Ver todas no ClinVar

Vias biológicas (Reactome)

1 via biológica associada aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
1Fase 11
·Pré-clínico2
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 3 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Leucoencefalopatia de Cree

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

7 ensaios clínicos encontrados, 2 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
1 papers (10 anos)
#1

Infantile-Onset Vanishing White Matter Disease in an Azerbaijani Infant With a Homozygous EIF2B5 p.(Arg195His) Variant.

Cureus2026 Feb

An eight-month-old Azerbaijani male infant, born to consanguineous (first-cousin) parents, presented with developmental regression and daily seizures following a febrile illness. He achieved head control at six months (delayed). During the same month, a rotavirus infection (fever, vomiting, and diarrhea) precipitated focal and generalized seizures. Neurological examination at eight months demonstrated severe hypotonia, hyperreflexia, and markedly reduced voluntary movements, with preserved visual and auditory responses. Brain MRI showed diffuse supra- and infratentorial white matter T1 hypointensity and marked T2 hyperintensity, with loss of subcortical U-fibers and deep white matter fluid-attenuated inversion recovery hypointensity consistent with rarefaction/degeneration, while the basal ganglia and cerebral cortex were relatively spared, an imaging pattern highly suggestive of advanced vanishing white matter (VWM) disease. Genetic testing identified a homozygous EIF2B5 c.584G>A (p.Arg195His) variant, supporting the diagnosis. This case illustrates subacute infantile VWM with stressor-related neurologic deterioration, hypotonia, and refractory seizures, underscoring the value of early molecular diagnosis in infants with suspected leukodystrophy.

#2

The impact of vanishing white matter on unaffected family members.

Orphanet journal of rare diseases2025 Aug 26

Vanishing White matter (VWM) is one of the more prevalent leukodystrophies, caused by biallelic pathogenic variants in any of the EIF2B1-5 genes. It is characterized by chronic progressive neurological deterioration and additional stress-provoked episodes of rapid decline, leading to severe neurological impairment and early death. The impact of VWM on unaffected family members has not been investigated. This international cross-sectional study enrolled parents, partners, and unaffected siblings. We used online administration of (1) health-related quality of life questionnaires (quantitative, comprising the EuroQol-5-Dimensions [EQ5-D]-5-Levels questionnaire [EQ-5D-5L], EuroQol-5-Dimensions-Youth-3-Levels questionnaire [EQ-5D-Y-3L], Pediatric Quality of Life Family Impact Module [PedsQL™-FIM], PedsQL™ Child-Adult Self Report [PedsQL™-SC]); (2) VWM-specific customized questionnaires (quantitative, comprising the impact of VWM inventory questionnaires for parents, partners and siblings); and (3) in-depth semi-structured interview (qualitative). A total of 100 family members were included: 52 mothers, 29 fathers, 13 unaffected siblings, and 6 partners. Mothers and partners scored significantly poorer on the EQ5D-5L than the reference norms. Fathers and mothers scored significantly poorer on the PedsQL™-FIM than the reference norms. Siblings scored similar to the reference norms on the EQ5D-5L and all domains of the PedsQL™-SC, with the lowest score on the emotional domain. Qualitative interviews revealed three main drivers of the impact of VWM: (1) lack of knowledge and empathy of healthcare professionals, (2) unpredictable disease course, and (3) caregiver responsibilities. Mothers reported substantial impacts on their emotional well-being and dissatisfaction with their professional development. Fathers commonly reported financial concerns and heightened family responsibility. Partners mentioned emotional exhaustion and difficulty in managing family responsibilities. Siblings frequently reported internal struggles, finding it challenging to express their feelings. Mothers and partners indicate a significant and consistent reduction in their quality of life on standardized questionnaires. Qualitative interviews revealed in-depth details of VWM's impact on all family members. Improved healthcare communication, symptom management resources, and support networks are essential for alleviating VWM's impact on families. This study emphasizes the importance of tailored approaches to supporting family members of VWM patients and enhancing their quality of life.

Publicações recentes

Ver todas no PubMed

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Leucoencefalopatia de Cree.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Leucoencefalopatia de Cree

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Infantile-Onset Vanishing White Matter Disease in an Azerbaijani Infant With a Homozygous EIF2B5 p.(Arg195His) Variant.
    Cureus· 2026· PMID 41727804mais citado
  2. The impact of vanishing white matter on unaffected family members.
    Orphanet journal of rare diseases· 2025· PMID 40859278mais citado
  3. A Japanese girl with an early-infantile onset vanishing white matter disease resembling Cree leukoencephalopathy.
    Brain Dev· 2015· PMID 25457085recente
  4. Neuroimaging and neurophysiology studies in carriers of cree leukoencephalopathy.
    Can J Neurol Sci· 2011· PMID 21320845recente
  5. [CACH/VWM syndrome and leucodystrophies related to EIF2B mutations].
    Rev Neurol (Paris)· 2007· PMID 17878805recente
  6. Population history and its impact on medical genetics in Quebec.
    Clin Genet· 2005· PMID 16143014recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:99854(Orphanet)
  2. OMIM OMIM:603896(OMIM)
  3. MONDO:0020507(MONDO)
  4. GARD:16919(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q3508563(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Leucoencefalopatia de Cree
Compêndio · Raras BR

Leucoencefalopatia de Cree

ORPHA:99854 · MONDO:0020507
🇧🇷 Brasil SUS
Internações
890/ano
Prevalência BR
1:60000
Custo SUS
R$ 45.670/internação
Dados
DATASUS 2024
Geral
CID-10
E75.2 · Outras esfingolipidoses
CID-11
Ensaios
2 ativos
MedGen
UMLS
C1858991
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades